Bookmark and Share

Alonso  Heredia

Alonso Heredia Ph.D.

Academic Title: Assistant Professor
Primary Appointment: Medicine
Location: 725 W. Lombard Street N549

Personal History:

Positions and Employment

1995 -1997: Postdoctoral training. Lab Molecular Virology. Food and Drug Administration. Bethesda
1997 - 2008: Research Associate, Clinical Research Div, IHV, Univ of Maryland School of Medicine
2008 – present: Assistant Professor, Clinical Research Div, IHV, Univ of Maryland School of Medicine


Recent Publications

Margolis D, Heredia A, Gaywee J, Oldach D, Drusano G, Redfield R. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity.  J AIDS and Human Retrovirology 1999, 21: 362-370

Heredia A, Margolis D, Oldach D, Hazen R, Le N, Redfield R. Abacavir  in combination with the Inosine Monophosphate Dehydrogenase (IMPDH)-Inhibitor Mycophenolic Acid is active against multidrug-resistant  HIV-1. J AIDS and Human Retrovirology 1999, 22: 406-407

Heredia A, Davis C, Redfield R. The synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogs combined with a natural product, resveratrol. J AIDS and Human Retrovirology 2000, 25: 246-255

Heredia A, Davis C, Le N, Dominique JK, Redfield RR. Differential HIV-suppressive activity of RT inhibitors in resting and activated peripheral blood lymphocytes: implications for therapy. J Human Virology 2001, 4: 113-122.

Heredia A, Davis C, Amoroso A, Dominique JK, Le N, Klingebiel E, Reardon E, Zella D, Redfield RR. Induction of G1 cycle arrest in T lymphocytes results in increased extracellular levels of beta-chemokines: a strategy to inhibit R5 HIV-1. Proc Natl Acad Sci USA 2003, 100: 4179-4184.

Heredia A, Amoroso A, Davis C, Le N, Reardon E, Dominique JK, Klingebiel E, Gallo RC, Redfield RR. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci USA 2003, 100: 10411-10416.

Naicker KP, Li H, Heredia A, Song H, Wang LX. Design and synthesis of alpha Gal-conjugated peptide T20 as novel antiviral agent for HIV-immunotargeting. Org Biomol Chem. 2004, 7: 660-664.

Wang LX, Heredia A, Song H, Zhang Z, Yu B, Davis C, Redfield R. Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity. J Pharm Sci. 2004, 10: 2448-2457.

Li H, Song H, Heredia A, Le N, Redfield R, Lewis G, Wang LX. Synthetic bivalent CD4-mimetic miniproteins show enhanced anti-HIV activity over the monovalent miniprotein. Bioconjug Chem. 2004, 15: 783-789.

Wang J, Le N, Heredia A, Song H, Redfield R, Wang LX. Modification and structure-activity  relationship of a small molecule HIV-1 inhibitor targeting the viral envelope glycoprotein gp120. Org Biomol Chem 2005, 3: 1781-1786.

Heredia A, Davis C, Amoroso A, Taylor G, Le N, Bamba D, Redfield R. In vitro suppression of latent HIV-1 activation by vitamin E: potential clinical implications. AIDS 2005, 19: 836-837.

Heredia A, Davis c, Bamba D, Le N, Gwarzo M, Sadowska M, Gallo R, Redfield R. Indirubin-3’-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication. AIDS 2005, 19: 2087-2095.

Sajadi M, Heredia A, Le N, Constantine N, Redfield R. HIV-1 natural viral suppressors: control of viral replication in the absence of therapy. AIDS 2007, 21: 517-519.

Heredia A, Gilliam B, Devico A, Le N, Bamba D, Flinko R, Lewis G, Gallo RC, Redfield RR. CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1. AIDS. 2007, 21:1317-1322.

Heredia A, Gilliam B, Latinovic O, Le N, Bamba D, Devico A, Melikyan GB, Gallo RC, Redfield RR. Rapamycin reduces CCR5 density levels on CD4 T cells and this effect results in potentiation of Enfuvirtide (T-20) against R5 HIV-1 in vitro. Antimicrob Agents Chemother. 2007, 51:2482-2496.

Gilliam B, Heredia A, DeVico A, Le N, Bamba D, Bryant J, Pauza D, Redfield R. Rapamycin reduces CCR5 m-RNA levels in macaques: Potential applications in HIV-1 prevention and treatment. AIDS 2007, 21:2108-2110.

Taylor B, Foulke J, Flinko R, Heredia A, Devico A, Reitz M. An Alteration of HIV gp41 leading to reduced CCR5 dependence and CD4 independence. J Virol 2008, 82(11): 5460-5471.

Heredia A, Latinovic O, Gallo R, Melikyan G, Reitz M, Le N, Redfield R. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc Natl Acad Sci USA 2008, 105: 20476-20481.

Huang W, Groothuys S, Heredia A, Kuijpers BH, Rutjes FP, van Delft FL, Wang LX. Enzymatic glycosylation of triazole-linked GlcNAc/Glc-peptides: synthesis, stability and anti-HIV activity of triazole-linked HIV-1 gp41 glycopeptide C34 analogues. Chembiochem. 2009, 10(7): 1234-1242

Latinovic O, Heredia A, Gallo RC, Reitz M, Le N, Redfield RR.  Rapamycin Enhances Aplaviroc Anti-HIV Activity:  Implications for the Clinical Development of Novel CCR5 Antagonists. Antiviral Research 2009, 83: 86-89.

Latinovic O, Kuruppu J, Davis C, Heredia A. Pharmacotherapy of HIV-1 infection: focus on Maraviroc. Clin Med Ther (submitted).